^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

STEAP1 expression

i
Other names: STEAP1, STEAP Family Member 1, Six Transmembrane Epithelial Antigen Of The Prostate 1, Six-Transmembrane Epithelial Antigen Of Prostate 1 , Metalloreductase STEAP1, STEAP1 Metalloreductase, PRSS24, STEAP, Six Transmembrane Epithelial Antigen Of The Prostate
Entrez ID:
19d
STEAP3 Affects Ovarian Cancer Progression by Regulating Ferroptosis through the p53/SLC7A11 Pathway. (PubMed, Mediators Inflamm)
Through tumorigenic experiments in nude mice, we finally verified that the knockdown of STEAP3 could inhibit tumor growth in vivo by promoting ferroptosis through the p53 pathway. Overall, our study identified a novel therapeutic target for ferroptosis in OC and explored its specific mechanism of action.
Journal
|
SLC7A11 (Solute Carrier Family 7 Member 11) • STEAP3 (STEAP3 Metalloreductase)
|
STEAP1 expression
2ms
Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. (PubMed, Int J Mol Sci)
In conclusion, the CD8sp_41BBz STEAP1 CAR T cells had superior expansion and survival in vitro and in vivo, compared to the IgGsp_CD28z counterpart, and a less exhausted phenotype upon repeated antigen exposure. Such persistence may be important for clinical efficacy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2RA (Interleukin 2 receptor, alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • STEAP1 (STEAP Family Member 1) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
|
PD-1 expression • LAG3 expression • STEAP1 expression
4ms
Six Transmembrane Epithelial Antigen 1 as a Prognostic Biomarker in Carcinomas: A Meta-Analysis. (PubMed, Front Biosci (Landmark Ed))
STEAP1 could regulate various biological functions in tumors and predict prognosis as a novel biomarker in a number of cancer types.
Retrospective data • Journal
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
4ms
Molecular characterization of STEAP3 in lung squamous cell carcinoma: Regulating EGFR to affect cell proliferation and ferroptosis. (PubMed, Arch Biochem Biophys)
EGFR overexpression reversed the effects of STEAP3 silencing on H2170 cell viability, proliferation, oxidative stress, and ferroptosis. To summarize, the inhibition of STEAP3/EGFR may serve as a promising therapeutic target for LUSC treatment, as it can suppress LUSC proliferation and promote lipid peroxidation and ferroptosis.
Journal
|
EGFR (Epidermal growth factor receptor) • STEAP1 (STEAP Family Member 1) • STEAP3 (STEAP3 Metalloreductase)
|
EGFR overexpression • STEAP1 expression
4ms
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. (PubMed, J Clin Invest)
Further, AZD0754 enforced robust, dose-dependent in vivo efficacy in STEAP2-expressing cancer cell line-derived and patient-derived xenograft mouse models, and exhibited encouraging preclinical safety. Together, these data underscore the therapeutic tractability of STEAP2 in prostate cancer as well as build confidence in the specificity, potency, and tolerability of this potentially first-in-class CAR-T therapy.
Journal • CAR T-Cell Therapy • IO biomarker
|
TGFB1 (Transforming Growth Factor Beta 1)
|
STEAP1 expression
4ms
STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and PI3K-AKT pathway. (PubMed, Cancer Biomark)
STEAP3 plays significant roles in the advancement of glioma by regulating immune microenvironment and PI3K-AKT pathway. It has the potential to serve as a therapy target for glioma.
Journal
|
STEAP3 (STEAP3 Metalloreductase)
|
STEAP1 expression
5ms
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. (PubMed, Cancer Discov)
Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate cancer.
P1 data • Journal • Metastases
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
|
xaluritamig (AMG 509)
5ms
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity Against Prostate Cancer. (PubMed, Cancer Discov)
The avidity-driven activity of AMG 509 enables selectivity for tumor cells with high STEAP1 expression compared with normal cells. AMG 509 is the first STEAP1 TCE to advance to clinical testing, and we report a case study of a mCRPC patient who achieved an objective response on AMG 509 treatment.
Journal
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
|
xaluritamig (AMG 509)
6ms
Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) (ESMO Asia 2023)
Preliminary PK showed dose-proportional increase in exposure with a mean terminal half-life of approximately 3-4 days. Conclusions Xaluritamig was tolerable with low-grade CRS (occurring primarily cycle 1) with encouraging preliminary efficacy in heavily pretreated pts with mCRPC.
Clinical • P1 data • Metastases
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
|
xaluritamig (AMG 509)
7ms
Immune responses of six-transmembrane epithelial antigen of the prostate 4 functions as a novel biomarker in gastric cancer. (PubMed, World J Clin Oncol)
The current findings suggest an oncogenic role for STEAP4 in GC, with significantly high levels being associated with poor prognosis. Investigation of the GC tumor microenvironment suggests the potential function of STEAP4 is connected with the infiltration of diverse immune cells, which may contribute to the regulation of the tumor microenvironment. In conclusion, STEAP4 may serve as a potential therapeutic target for GC to improve the immune infiltration, as well as serve as a prognostic biomarker for judging the prognosis and immune infiltration status of GC.
Journal • IO biomarker
|
CD4 (CD4 Molecule) • STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
7ms
Six-transmembrane epithelial antigen of prostate 3 (STEAP3) is a potential prognostic biomarker in clear cell renal cell carcinoma that correlates with M2 macrophage infiltration and epithelial-mesenchymal. (PubMed, Cancer Rep (Hoboken))
In a diverse range of cancers, STEAP3 might serve as a biomarker for determining the prognosis as well as a predictor of immunotherapy responsiveness. STEAP3 is a novel biological marker for determining prognosis, and it also performs a remarkable function in the promotion of tumor growth in ccRCC by enhancing invasion and EMT, as well as by triggering the recruitment and polarization of M2 macrophages.
Journal • IO biomarker
|
CDH1 (Cadherin 1) • STEAP1 (STEAP Family Member 1) • STEAP3 (STEAP3 Metalloreductase)
|
STEAP1 expression
8ms
Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) (ESMO 2023)
Preliminary PK showed dose-proportional increase in exposure with a mean terminal half-life of approximately 3-4 days. Table: 1765O Lower DLs (DL 1–7) Higher DLs (DL8–15) Overall PSA evaluable N = 43 N = 46 N = 89 PSA ≥ 50%, n (%) 17 (39.5) 25 (54.3) 42 (47.2) PSA ≥ 90%, n (%) 8 (18.6) 16 (34.8) 24 (27.0) RECIST evaluable N = 30 N = 36 N = 66 PR, n (%) 1 (3.3) 14 (38.9) 15 (22.7) SD, n (%) 18 (60.0) 12 (33.3) 30 (45.5) Conclusions Xaluritamig was tolerable with low-grade CRS (occurring primarily cycle 1) with encouraging preliminary efficacy in heavily pretreated pts with mCRPC.
Clinical • P1 data • Metastases
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
|
xaluritamig (AMG 509)
9ms
Investigating STEAP2 as a potential therapeutic target for the treatment of aggressive prostate cancer. (PubMed, Cell Mol Biol (Noisy-le-grand))
The migratory and invasive potential of knockout cells were also decreased. These data suggest that STEAP2 has a functional role in driving aggressive prostate cancer traits and could provide a novel therapeutic target for the treatment of prostate cancer.
Journal
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
12ms
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. (PubMed, Nat Commun)
STEAP1 antigen escape is a recurrent mechanism of treatment resistance and is associated with diminished tumor antigen processing and presentation. The application of tumor-localized interleukin-12 (IL-12) therapy in the form of a collagen binding domain (CBD)-IL-12 fusion protein combined with STEAP1 CAR T cell therapy enhances antitumor efficacy by remodeling the immunologically cold tumor microenvironment of prostate cancer and combating STEAP1 antigen escape through the engagement of host immunity and epitope spreading.
Journal • CAR T-Cell Therapy • IO biomarker • Metastases
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
12ms
STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel. (PubMed, Int J Mol Sci)
Besides, these chemotherapeutic drugs may stimulate the cell growth of PCa cells knocked down for STEAP1. In conclusion, this study demonstrated that STEAP1 expression levels might influence the response of PCa cells to chemotherapeutics drugs, indicating that the use of paclitaxel, docetaxel, or cabazitaxel may lead to harmful effects in PCa cells with decreased expression of STEAP1.
Journal
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
|
paclitaxel • docetaxel • cabazitaxel
1year
Prognostic Significance of Iron Metabolism Related Genes in Human Lung Adenocarcinoma. (PubMed, Cancer Manag Res)
Multiple iron metabolism related genes including STEAP1 and STEAP2 are significantly associated with the prognosis of LUAD patients. STEAP1 and STEAP2 might affect the prognosis of LUAD patients partially through immune cell infiltration, gene mutation and drug resistance, which indicated they were independent prognostic factors for LUAD patients.
Journal
|
TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • CD4 (CD4 Molecule) • STEAP1 (STEAP Family Member 1)
|
TP53 mutation • STK11 mutation • STEAP1 expression
1year
Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy. (PubMed, Biomedicines)
In conclusion, the SwR confers CAR T cells with potent and durable in vitro functionality in TGFβ-rich environments. The SwR may be used as an add-on construct for CAR T cells or other forms of adoptive cell therapy.
Journal
|
IL2 (Interleukin 2) • STEAP1 (STEAP Family Member 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
STEAP1 expression
1year
STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide. (PubMed, Mol Med Rep)
Overall, the cellular and molecular effects were similar between LNCaP wild‑type and LNCaP‑STEAP1 knockdown cells, except for c‑myc expression levels, where a cumulative effect between anti‑androgen treatment and STEAP1 knockdown was observed. The effect of STEAP1 knockdown alone or combined with anti‑androgens in c‑myc levels is required to be addressed in future studies.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • STEAP1 (STEAP Family Member 1)
|
MYC expression • STEAP1 expression
|
enzalutamide capsule • bicalutamide • Erleada (apalutamide)
over1year
Six-transmembrane epithelial antigen of prostate 3 promotes hepatic insulin resistance and steatosis. (PubMed, J Lipid Res)
Mechanistically, it interacts with transforming growth factor beta-activated kinase 1 (TAK1) to regulate the progression of NAFLD by promoting TAK1 phosphorylation and activating the TAK1- c-Jun N-terminal kinase (JNK)/p38 signaling pathway. Taken together, our results provide further insight into the involvement of STEAP3 in liver pathology.
Journal
|
STEAP1 (STEAP Family Member 1) • MAPK8 (Mitogen-activated protein kinase 8)
|
STEAP1 expression
over1year
STEAP2 promotes osteosarcoma progression by inducing epithelial-mesenchymal transition via the PI3K/AKT/mTOR signaling pathway and is regulated by EFEMP2. (PubMed, Cancer Biol Ther)
It is also worth noting that although EFEMP2 overexpression activated the PI3K/AKT/mTOR pathway promoting EMT, it did not affect osteosarcoma cells in which STEAP2 or Akt was knocked down. Thus, we can conclude that STEAP2 acts as an oncogene in osteosarcoma progression, while EFEMP2 enables PI3K/AKT/mTOR axis initiation and EMT by partly targeting STEAP2, thereby facilitating osteosarcoma cell infiltration and migration.
Journal
|
EGF (Epidermal growth factor) • ECM2 (Extracellular Matrix Protein 2)
|
STEAP1 expression
over1year
Harnessing tumor localized IL-12 to enhance STEAP1 CAR T cell therapy for prostate cancer (SITC 2022)
A strategy of combining CBD-IL-12 together with STEAP1 CAR T cell therapy enhances anti-tumor responses by remodeling the TME and engaging host immunity. Ethics Approval All mouse studies were performed in accordance with protocols approved by the Fred Hutchinson Cancer Center Institutional Animal Care and Use Committee and regulations of Comparative Medicine.
CAR T-Cell Therapy
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression • FOLH1 expression
over1year
Potential of six-transmembrane epithelial antigen of the prostate 4 as a prognostic marker for colorectal cancer. (PubMed, World J Gastrointest Oncol)
Our results provide an analysis of the expression of STEAP family members in CRC. Among different STEAP family members, STEAP4 plays a different role in CRC compared to STEAPs 1-3. In CRC, STEAP4 expression is not only lower than that in normal tissues, but it is also positively correlated with immune infiltration and immune-related biomarkers. These findings suggest that STEAP4 may be a potential biomarker for predicting CRC immune infiltration status.
Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2) • STEAP1 (STEAP Family Member 1)
|
MSI-H/dMMR • STEAP1 expression
over1year
Expression of STEAP-1 and p40 in Prostatic Carcinoma and Its Mimickers (clinicaltrials.gov)
P=N/A, N=70, Not yet recruiting, Sohag University | Initiation date: Aug 2022 --> Dec 2022
Trial initiation date
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
over1year
The copper-associated protein STEAP2 correlated with glioma prognosis and immune infiltration. (PubMed, Front Cell Neurosci)
Furthermore, we focused on STEAP2 and demonstrated that STEAP2 expression was relatively low in tumor tissues compared to normal tissues, implying a favorable prognosis. Our findings provide a foundation for future research targeting copper-related proteins and their immune microenvironment to improve prognosis and responses to immunotherapy.
Journal • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden)
|
STEAP1 expression
over1year
Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing mA-mediated degradation of STEAP3 mRNA. (PubMed, Mol Cancer)
Taken together, our study highlights the mechanisms of lncRNA STEAP3-AS1 in facilitating CRC progression involving the STEAP3-AS1/STEAP3/Wnt/β-catenin axis, which may provide novel diagnostic biomarkers or therapeutic targets to benefit CRC treatment. Hypoxia-induced HIF-1α transcriptionally upregulates the expression of lncRNA STEAP3-AS1, which interacts competitively with YTHDF2, thus upregulating mRNA stability of STEAP3 and consequent STEAP3 protein expression. The enhanced STEAP3 expression results in production of cellular ferrous iron (Fe), which induces the Ser 9 phosphorylation and inactivation of GSK3β, releasing β-catenin for nuclear translocation and contributing to subsequent activation of Wnt signaling to promote CRC progression.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
|
STEAP1 expression • HIF1A expression
over1year
Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer. (PubMed, Mol Ther Oncolytics)
Here, the CAR T cells infiltrated tumors and significantly inhibited tumor growth and extended survival in a STEAP1-dependent manner. We conclude that the STEAP1 CAR exhibits potent in vitro and in vivo functionality and can be further developed toward potential clinical use.
Journal
|
CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
over1year
Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer. (PubMed, Clin Chem)
The RAI2 protein functions as a transcriptional coregulator of the androgen response in prostate cancer cells. Detection of RAI2 gene expression in blood samples from patients with metastatic prostate cancer indicated the presence of circulating tumor cells.
Journal
|
CDH1 (Cadherin 1) • FOLH1 (Folate hydrolase 1) • KLK3 (Kallikrein-related peptidase 3)
|
AR expression • AR splice variant 7 • STEAP1 expression • FOLH1 expression
almost2years
New trial
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
over2years
Promoter Demethylation Upregulates STEAP1 Gene Expression in Human Prostate Cancer: In Vitro and In Silico Analysis. (PubMed, Life (Basel))
In addition, the involvement of HDAC in the regulation of STEAP1 mRNA expression was corroborated by a negative association between STEAP1 mRNA expression and HDAC4,5,7 and 9 in human PCa. In conclusion, our work indicates that STEAP1 overexpression in PCa can be driven by the hypomethylation of STEAP1 gene promoter.
Preclinical • Journal
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
over2years
Predictive potential of STEAP family for survival, immune microenvironment and therapy response in glioma. (PubMed, Int Immunopharmacol)
Finally, chemotherapy and immune therapy responses for high- and low-risk patients were predicted. In conclusion, this study systematically analyzed the role of STEAP family in glioma and established a model for predicting therapy response in patients with glioma.
Journal
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
over2years
Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer. (PubMed, Vaccines (Basel))
Immunotherapy involving Sipuleucel-T has increasingly drawn attention for prostate cancer management...The immune response against prostate cancer was greatly suppressed when the antigen targets were knocked out using CRISPR-Cas9. (4) In summary, our results provide the first evidence that a vaccine based on a fusion protein consisting of Ag85B and a prostate cancer octapeptide epitope with complete Freund's adjuvant (CFA), triggers a robust immune response and inhibits tumor growth in murine prostate cancer.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • IL2 (Interleukin 2) • STEAP1 (STEAP Family Member 1) • FOXP3 (Forkhead Box P3) • IL4 (Interleukin 4) • CD86 (CD86 Molecule)
|
STEAP1 expression
|
Provenge (sipuleucel-T)
over2years
Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells. (PubMed, Oncol Lett)
In conclusion, the knockdown of STEAP1 in liver cancer cell lines led to inhibition of cell proliferation involving G arrest by suppressing c-Myc. The present study provides a preclinical concept for STEAP1 as a druggable target in liver cancer.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • STEAP1 (STEAP Family Member 1)
|
MYC expression • STEAP1 expression
almost3years
Identification of a New Transcriptional Co-Regulator of STEAP1 in Ewing's Sarcoma. (PubMed, Cells)
Our results show that NKX2.2 is a co-regulator of STEAP1 expression and functions by interacting with the STEAP1 promoter at sites proximal to the reported EWSFLI1 sites. The co-operative interaction of NKX2.2 with EWSFLI1 in regulating STEAP1 holds potential as a new target for therapeutic interventions for ES.
Journal
|
EWSR1 (EWS RNA Binding Protein 1) • STEAP1 (STEAP Family Member 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
|
STEAP1 expression
almost3years
Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer. (PubMed, Front Oncol)
A functional role of STEAP4 intervention was established in HER2 overexpressing BC by pharmacological studies, where blockage of the STEAP4 pathway with an iron chelator (Deferiprone) in combination with the HER2 inhibitor Lapatinib led to a significant reduction in cell growth in vitro. Furthermore, siRNA mediated knockdown of STEAP4 also suppressed cell proliferation and enhanced the inhibition of Lapatinib in HER2 overexpressing BC, confirming its potential oncogenic role in BC. In conclusion, STEAP4 may represent a novel BC related biomarker and a potential pharmacological target for the treatment of HER2 overexpressing BC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • STEAP1 expression
|
lapatinib
3years
[VIRTUAL] Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). (ASCO-GU 2021)
Key inclusion criteria: men ≥18 years with histologically/cytologically confirmed mCRPC who are refractory to novel hormonal therapy (e.g., abiraterone and/or enzalutamide) and have failed 1–2 taxane regimens or are medically unsuitable for or have refused taxanes; ongoing castration with total serum testosterone ≤50 ng/dL; evidence of progressive disease; ECOG performance status 0–1; life expectancy ≥3 months; and adequate hematologic, renal, hepatic, and cardiac function. Key exclusion criteria: pure small cell or neuroendocrine carcinoma of the prostate; untreated CNS metastases or leptomeningeal disease; any anticancer therapy or immunotherapy, radiation therapy, or major surgery <4 weeks from first dose; history of or current autoimmune disease or any disease requiring immunosuppressive therapy (≤10 mg/d prednisone permitted); prior STEAP1-targeted therapy; infection requiring IV antimicrobials <7 days from first dose. The study opened in January 2020 and is recruiting patients.
Clinical • P1 data • IO biomarker
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
|
enzalutamide capsule • abiraterone acetate • xaluritamig (AMG 509)
3years
Six-transmembrane epithelial antigen of the prostate 1 expression promotes ovarian cancer metastasis by aiding progression of epithelial-to-mesenchymal transition. (PubMed, Histochem Cell Biol)
In human ovarian cancer, the STEAP1 gene is highly expressed, and its function is correlated with human ovarian cancer cell metastasis and growth. STEAP1 may be a possible target for suppressing ovarian cancer metastasis.
Journal
|
MMP2 (Matrix metallopeptidase 2) • STEAP1 (STEAP Family Member 1) • MMP9 (Matrix metallopeptidase 9)
|
STEAP1 expression
over3years
Comprehensive landscape of STEAP family functions and prognostic prediction value in glioblastoma. (PubMed, J Cell Physiol)
Finally, a prognostic nomogram combining age, gender, chemotherapy, radiotherapy, IDH1 status, and the risk score model based on STEAP2 and STEAP3 was built and further validated in TCGA and Chinese Glioma Genome Atlas (CGGA) cohorts via concordance index and calibration plot, which suggested a favorable value for prognosis prediction. In conclusion, our results provided a comprehensive analysis of the STEAP family and a model for the prognosis prediction of GBM.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • STEAP1 (STEAP Family Member 1)
|
STEAP1 expression
over3years
lncRNA STEAP3-AS1 Modulates Cell Cycle Progression via Affecting CDKN1C Expression through STEAP3 in Colon Cancer. (PubMed, Mol Ther Nucleic Acids)
Mechanistic investigations demonstrated that STEAP3-AS1 downregulation could increase the expression of cyclin-dependent kinase inhibitor 1C (CDKN1C) by STEAP3 upregulation. Overall, we identify the underlying role of MT1M-related lncRNA STEAP3-AS1 in colon cancer progression, which provides a novel strategy for colon cancer therapy.
Journal
|
CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C)
|
STEAP1 expression
over3years
Six-transmembrane epithelial antigen of the prostate 1 protects against increased oxidative stress via a nuclear erythroid 2-related factor pathway in colorectal cancer. (PubMed, Cancer Gene Ther)
Taken together, we identified high STEAP1 transcript levels leading to reduced ROS production that prevented apoptosis via the NRF2 pathway in CRC cells as a pathological mechanism in CRC. This study highlights the STEAP1-NRF2 axis as a therapeutic target for CRC and its manipulation as a novel strategy to conquer CRC.
Journal
|
STEAP1 (STEAP Family Member 1)
|
STEAP1 expression